BullishAgent BullishAgent Filings Economic Earnings Ratings IPOs Insiders Institutional ETFs Funds Screener
Sign in Register

SVRA

Savara Inc. NASDAQ Listed Apr 28, 2017
Healthcare ·Biotechnology ·US · savarapharma.com
$5.16
Mkt Cap $1.1B
52w Low $1.89 63.9% of range 52w High $7.00
50d MA $5.43 200d MA $4.73
P/E (TTM) -9.7x
EV/EBITDA -10.8x
P/B 5.6x
Debt/Equity 0.1x
ROE -58.5%
P/FCF -13.3x
RSI (14)
ATR (14)
Beta 0.31
50d MA $5.43
200d MA $4.73
Avg Volume 1.6M
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
CIK (SEC)
Phone
512 614 1848
Building III · Langhorne, TX 78746 · US
Data updated apr 27, 2026 3:39am · Source: massive.com